Teva, Medincell granted FDA review for long-acting antipsychotic
Teva Pharmaceutical (TEVA) and its European partner Medincell (MDCLF) announced that the FDA has accepted their marketing...
Tag: TEVA
Corcept falls as appeals court sides with Teva in Korlym patent dispute
Shares of Corcept Therapeutics (CORT) lost more than 20% on Thursday after a federal appeals court ruled against the company...
Teva, Sanofi report durable phase 2b efficacy for duvakitug in ulcerative colitis, Crohn’s disease
Teva Pharmaceutical (TEVA) and Sanofi (SNY) on Tuesday reported that their investigational TL1A antibody duvakitug showed...
Teva snaps six straight sessions of gains
Teva Pharmaceutical Industries (TEVA) shares snapped six straight sessions of gains, as the stock closed 0.4% lower at...
Earnings Snapshot: Teva Pharmaceutical Industries tops Q4 estimates; initiates FY26 outlook below forecast
*Other Operating Data Consensus Source: Bloomberg
Teva projects revenue drop in 2026 despite Q4 beat
Teva Pharmaceutical (TEVA) traded lower in the premarket on Wednesday after the generic drugmaker projected...
Teva Pharmaceutical Non-GAAP EPS of $0.96 beats by $0.32, revenue of $4.71B beats by $380M
Teva Pharmaceutical press release (TEVA): Q4 Non-GAAP EPS of $0.96 beats by $0.32. Revenue of $4.71B (+11.3% Y/Y) beats by...
Teva Pharmaceutical Q4 2025 Earnings Preview
Teva Pharmaceutical (TEVA) is scheduled to announce Q4 earnings results on Wednesday, January 28th, before market open. The...
Novo sued for working with Teva to delay generic Victoza
A class action lawsuit was filed in New York federal court on Friday accusing Novo Nordisk (NVO) of running a...
Teva Pharmaceutical sees 2025 EPS at higher range of outlook
Teva Pharmaceutical Industries (TEVA) said that it anticipates its 2025 diluted EPS will be at the higher end of its...